Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy

International Immunopharmacology

Volumn 3, Issue 3, 2003, Pages 335-344

  Tschöpe, Carsten ^a   Seidl, Ulrich ^b   Reinecke, Alexander ^c   Riester, Udo ^b   Graf, Kristof ^d   Schultheiss, Heinz Peter ^a   Hilgenfeldt, Ulrich ^b   Unger, Thomas ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Angiotensin converting enzyme; Bradykinin; Diabetic nephropathy; HOE 140; Kallikrein kinin system; Neutral endopeptidase 24.11; Ramipril

Indexed keywords

BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; LOW MOLECULAR WEIGHT KININOGEN; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; RAMIPRIL; STREPTOZOCIN;

ANIMAL EXPERIMENT; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; KALLIKREIN KININ SYSTEM; KIDNEY CORTEX; KIDNEY INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RAT;

EID: 0037333883     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(02)00273-4     Document Type: Conference Paper

References (36)

1. Zatz R. Haemodynamically mediated glomerular injury: the end of a 15-year-old controversy? Curr. Opin. Nephrol. Hypertens. 5:1996;468-475.
2. Hostetter T.H., Troy J.L., Brenner B.M. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int. 19:1981;410-415.
3. Hirose K., Østerby R., Nozawa M., Gunderson H.J.G. Development of glomerular lesions in experimental long-term diabetes in the rat. Kidney Int. 21:1982;689-695.
4. Evan A.P., Mong S.A., Gattone V.H., Conners B.A., Aronoff G.R.et al. The effect of streptozotocin and streptozotocin-induced diabetes on the kidney. Renal Physiol. (Basel). 7:1984;78-89.
5. O'Donnell M.P., Kasiske B.L., Keane W.F. Glomerular hemodynamic and structural alterations in experimental diabetes. FASEB J. 2:1988;2339-2347.
6. Jaffa A.A., Miller D.H., Bailey G.S., Chao J., Margolius H.S.et al. Abnormal regulation of renal kallikrein in experimental diabetes. J. Clin. Invest. 80:1987;1651-1659.
7. Margolius H.S. Tissue kallikreins and kinins: regulation and roles in hypertensive and diabetic diseases. Annu. Rev. Pharmacol. Toxicol. 29:1989;336-343.
8. Correa-Rotter R., Hostetter T.H., Rosenberg M.E. Renin and angiotensinogen gene expression in experimental diabetes mellitus. Kidney Int. 41:1992;796-804.
9. Anderson S., Jung F.F., Ingelfinger J.R. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am. J. Physiol. 265:1993;F477-F486.
10. Kennefick T.M., Oyama T.T., Thompson M.M., Jora J.P., Anderson S. Enhanced renal sensitivity to angiotensin actions in diabetes mellitus in the rat. Am. J. Physiol. 271:1996;F595-F602.
11. Tschöpe C., Gavriluk V., Reinecke A., Seidl U., Riester U.et al. Bradykinin excretion is increased in severely hyperglycemic streptozotocin-diabetic rats. Immunopharmacology. 33:1996;344-348.
12. Tschöpe C., Yu M., Reinecke A., Csikos T., Hilgenfeldt U.et al. Renal expression of two rat kallikrein genes under diabetic conditions. J. Hypertens. 15:1997;1711-1714.
13. Tschöpe C., Reinecke A., Seidl U., Yu M., Gavriluk V.et al. Functional, biochemical, and molecular biological investigations of renal kallikrein-kinin system in diabetic rats. Am. J. Physiol. 277:1999;H2333-H2340.
14. Ritz E., Orth S.R., Strzelczyk P. Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease. J. Hypertens. 15(Suppl. 2):1997;S21-S26.
15. Jaffa A.A., Rust P.F., Mayfield R.K. Kinin, a mediator of diabetes-induced glomerular hyperfiltration. Diabetes. 44:1995;156-160.
16. Komers R., Cooper M.E. Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins. Am. J. Physiol. 268:1995;F588-F594.
17. Allen T.J., Cao Z., Youssef S., Hulthen L., Cooper M.E. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies. Diabetes. 46:1997;1612-1618.
18. Vora J.P., Oyama T.T., Thompson M.M., Anderson S. Interactions of the kallikrein-kinin and renin-angiotensin systems in experimental diabetes. Diabetes. 46:1997;107-112.
19. Jaffa A.A., Chai K.X., Chao J., Chao L., Mayfield R.K. Effects of diabetes and insulin on expression of kallikrein and renin genes in the kidney. Kidney Int. 41:1992;789-795.
20. Kühnle H.F., Linzmeier P., Doerge L. Determination of glomerular filtration rate in rats. Gretz N., Strauch M. Experimental and genetic rat models of chronic renal failure. 1989;331-336 Karger, Basel.
21. Hilgenfeldt U., Linke R., Riester U., König W., Breipohl G. Strategy of measuring bradykinin and kallidin and their concentration in plasma and urine. Anal. Biochem. 228:1995;35-41.
22. Walther T., Siems W.-E., Hauke D., Spillmann F., Dendorfer A., Krause W.et al. AT1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in rats. FASEB J. 2002;. [in press].
23. Gainer J.V., Morrow J.D., Loveland A., King D.J., Brown N.J. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N. Engl. J. Med. 339:1998;1285-1292.
24. Tschöpe C., Schultheiss H.-P., Walther T. Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade. J. Cardiovasc. Pharmacol. 39:2002;478-487.
25. Siragy H.M., Jaffa A.A., Margolius H.S., Carey R.M. Renin-angiotensin system modulates renal bradykinin production. Am. J. Physiol. 271:1996;R1090-R1995.
26. Carey R.M., Wang Z.Q., Siragy H.M. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension. 35:2000;155-163.
27. Bao G., Gohlke P., Qadri F., Unger Th. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension. 20:1992;74-79.
28. Kon V., Fogo A., Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int. 44:1993;450-545.
29. Mac Dougall M., Cowley B., Wiegmann T. Bradykinin mediates effects of ramipril on diabetic glomerular hypertrophy and albuminuria independent of blood pressure effect. J. Am. Soc. Nephrol. 6:1996;A1044.
30. Dunn M.J. Prostaglandins, angiotensin II, and proteinuria. Nephron. 55(Suppl. 1):1990;S30-S37.
31. Yasujima M., Yoshida K., Kanazawa M., Kohzuki M., Omata K.et al. Urinary active kallikrein and diabetic impairments in streptozotocin-treated rats. Tohoku J. Exp. Med. 171:1993;135-144.
32. Fischer J.W., Tschöpe C., Reinecke A., Giachelli C.M., Unger Th. Upregulation of ostepontin expression in renal cortex of streptozotocin-induced diabetic rats is mediated by bradykinin. Diabetes. 47:1998;1512-1518.
33. Hutchison F.N., Cui X., Webster S.K. The antiproteinuric effect of converting enzyme inhibitors is dependent on kinin. J. Am. Soc. Nephrol. 6:1995;1216-1222.
34. Tanaka R., Kon V., Yoshimasa T., Ichikawa I., Fogo A. Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int. 45:1994;537-543.
35. Cellier E., Duchene J., Pecher C., Alric C., Bascands J.L.et al. B2 receptor activation reduces Erk1 and Erk2 phosphorylation induced by insulin-like growth factor-1, platelet-derived growth factor-BB, and high glucose in rat isolated glomeruli. Can. J. Physiol. Pharm. 80:2002;341-345.
36. Bascands J.L., Pecher C., Bompart G., Rakotoarivony J., Leung-Tack J.et al. Bradykinin-induced in vitro contraction of rat mesangial cells via a B2 receptor type. Am. J. Physiol. 267:1994;F871-F878.